Earnings results for Acceleron Pharma (NASDAQ:XLRN)
Acceleron Pharma Inc. is expected* to report earnings on 11/05/2020 after market close. The report will be for the fiscal Quarter ending Sep 2020. According to Zacks Investment Research, based on 8 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.55. The reported EPS for the same quarter last year was $-0.86.
Acceleron Pharma last issued its earnings data on August 6th, 2020. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.21. The business had revenue of $39.75 million for the quarter, compared to analyst estimates of $30.08 million. Its revenue was up 43.7% compared to the same quarter last year. Acceleron Pharma has generated ($2.38) earnings per share over the last year. Acceleron Pharma has confirmed that its next quarterly earnings report will be published on Thursday, November 5th, 2020.
Analyst Opinion on Acceleron Pharma (NASDAQ:XLRN)
13 Wall Street analysts have issued ratings and price targets for Acceleron Pharma in the last 12 months. Their average twelve-month price target is $124.54, predicting that the stock has a possible upside of 12.32%. The high price target for XLRN is $155.00 and the low price target for XLRN is $73.00. There are currently 1 sell rating, 1 hold rating, 10 buy ratings and 1 strong buy rating for the stock, resulting in a consensus rating of “Buy.”
Acceleron Pharma has received a consensus rating of Buy. The company’s average rating score is 2.85, and is based on 10 buy ratings, 1 hold rating, and 1 sell rating. According to analysts’ consensus price target of $124.54, Acceleron Pharma has a forecasted upside of 12.3% from its current price of $110.88. Acceleron Pharma has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.
Dividend Strength: Acceleron Pharma (NASDAQ:XLRN)
Acceleron Pharma does not currently pay a dividend. Acceleron Pharma does not have a long track record of dividend growth.
Insiders buying/selling: Acceleron Pharma (NASDAQ:XLRN)
In the past three months, Acceleron Pharma insiders have sold more of their company’s stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,758,556.00 in company stock. Only 2.50% of the stock of Acceleron Pharma is held by insiders. 79.78% of the stock of Acceleron Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.
Earnings and Valuation of Acceleron Pharma (NASDAQ:XLRN
Earnings for Acceleron Pharma are expected to decrease in the coming year, from ($2.47) to ($2.50) per share. The P/E ratio of Acceleron Pharma is -42.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Acceleron Pharma is -42.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Acceleron Pharma has a P/B Ratio of 13.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.
More latest stories: here